Samsung Bioepis' Knockoff Latest Competition For Johnson & Johnson's Blockbuster, Remicade

JNJ’s Remicade earned close to $7 billion last year, making it by far the biggest drug in their portfolio but the FDA has approved a new knockoff which may finally start to shift the market dynamics toward greater competition with lower prices.